

# Alan Winston

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5194872/alan-winston-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

93  
papers

1,799  
citations

25  
h-index

40  
g-index

99  
ext. papers

2,472  
ext. citations

4.6  
avg, IF

4.61  
L-index

#	Paper	IF	Citations
93	Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial.. <i>EClinicalMedicine</i> , <b>2022</b> , 44, 101262	11.3	8
92	Major revision version 11.0 of the European AIDS Clinical Society Guidelines 2021.. <i>HIV Medicine</i> , <b>2022</b> ,	2.7	4
91	CD4/CD8 Ratio and the Risk of Kaposi Sarcoma or Non-Hodgkin Lymphoma in the Context of Efficiently Treated Human Immunodeficiency Virus (HIV) Infection: A Collaborative Analysis of 20 European Cohort Studies. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 73, 50-59	11.6	6
90	Correlation between computerised and standard cognitive testing in people with HIV and HIV-negative individuals. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , <b>2021</b> , 33, 1296-1307	2.3	3
89	Sleep Disorders in Human Immunodeficiency Virus: A Substudy of the Pharmacokinetics and Clinical Observations in People Over Fifty (POPPY) Study. <i>Open Forum Infectious Diseases</i> , <b>2021</b> , 8, ofaa561	1	7
88	Predictive value of neurological symptoms in persons with suspected neurosyphilis. <i>Sexually Transmitted Infections</i> , <b>2021</b> ,	2.8	1
87	Moving on From HAND: Why We Need New Criteria for Cognitive Impairment in Persons Living With Human Immunodeficiency Virus and a Proposed Way Forward. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 73, 1113-1118	11.6	5
86	Mortality and AIDS-defining events among young people following transition from paediatric to adult HIV care in the UK. <i>HIV Medicine</i> , <b>2021</b> , 22, 631-640	2.7	1
85	The symptomatology of cerebrospinal fluid HIV RNA escape: a large case-series. <i>Aids</i> , <b>2021</b> , 35, 2341-2346	5.5	2
84	Response to: Asymptomatic neurocognitive impairment is a risk for symptomatic decline over a 3-year study period. <i>Aids</i> , <b>2021</b> , 35, 1152-1153	3.5	
83	Correlation between CSF and blood neurofilament light chain protein: a systematic review and meta-analysis. <i>BMJ Neurology Open</i> , <b>2021</b> , 3, e000143	1.5	8
82	Associations between plasma nucleoside reverse transcriptase inhibitors concentrations and cognitive function in people with HIV. <i>PLoS ONE</i> , <b>2021</b> , 16, e0253861	3.7	0
81	Objective and subjective rapid frailty screening tools in people with HIV. <i>HIV Medicine</i> , <b>2021</b> , 22, 146-150	2.7	2
80	Respiratory symptoms and chronic bronchitis in people with and without HIV infection. <i>HIV Medicine</i> , <b>2021</b> , 22, 11-21	2.7	3
79	"I have failed to separate my HIV from this pain": the challenge of managing chronic pain among people with HIV. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , <b>2021</b> , 1-9	2.2	1
78	Agreement between self-reported and objective measures of sleep in people with HIV and lifestyle-similar HIV-negative individuals. <i>Aids</i> , <b>2021</b> , 35, 1051-1060	3.5	2
77	Sleep health and cognitive function among people with and without HIV: the use of different machine learning approaches. <i>Sleep</i> , <b>2021</b> , 44,	1.1	1

76	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. <i>Lancet HIV,the</i> , <b>2021</b> , 8, e474-e485	7.8	62
75	No evidence of neuronal damage as measured by neurofilament light chain in a HIV cure study utilising a kick-and-kill approach. <i>Journal of Virus Eradication</i> , <b>2021</b> , 7, 100056	2.8	
74	Cerebral function parameters in people with HIV switching integrase inhibitors: a randomized controlled trial. <i>HIV Research and Clinical Practice</i> , <b>2021</b> , 1-9	1.7	
73	Correlation between cerebrospinal fluid and plasma neurofilament light protein in treated HIV infection: results from the COBRA study. <i>Journal of NeuroVirology</i> , <b>2021</b> , 1	3.9	0
72	Factors associated with obesity in the Pharmacokinetic and Clinical Observations in People over Fifty (POPPY) cohort: an observational cross-sectional analysis. <i>HIV Medicine</i> , <b>2020</b> , 21, 441-452	2.7	2
71	Response to: How helpful are the European AIDS Clinical Society cognitive screening questions in predicting cognitive impairment in an aging, well-treated HIV-positive population? <i>HIV Medicine</i> , <b>2020</b> , 21, e17-e18	2.7	0
70	Changes in functional connectivity in people with HIV switching antiretroviral therapy. <i>Journal of NeuroVirology</i> , <b>2020</b> , 26, 754-763	3.9	5
69	Plasma nucleotide reverse transcriptase inhibitor concentration and their associations with liver and renal parameters in people living with HIV. <i>Aids</i> , <b>2020</b> , 34, 790-793	3.5	1
68	Cognitive disorders in people living with HIV. <i>Lancet HIV,the</i> , <b>2020</b> , 7, e504-e513	7.8	26
67	Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2020</b> , 75, 628-639	5.1	5
66	The predictors of pain extent in people living with HIV. <i>Aids</i> , <b>2020</b> , 34, 2071-2079	3.5	3
65	Comorbidity indices in people with HIV and considerations for coronavirus disease 2019 outcomes. <i>Aids</i> , <b>2020</b> , 34, 1795-1800	3.5	5
64	2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0. <i>HIV Medicine</i> , <b>2020</b> , 21, 617-624	2.7	46
63	The development and validation of a novel LC-MS/MS method for the quantification of cenicriviroc in human plasma and cerebrospinal fluid. <i>Biomedical Chromatography</i> , <b>2020</b> , 34, e4711	1.7	1
62	Magnetic Resonance Imaging of Cerebral Small Vessel Disease in Men Living with HIV and HIV-Negative Men Aged 50 and Above. <i>AIDS Research and Human Retroviruses</i> , <b>2019</b> , 35, 453-460	1.6	5
61	Level of agreement between frequently used cardiovascular risk calculators in people living with HIV. <i>HIV Medicine</i> , <b>2019</b> , 20, 347-352	2.7	9
60	Cerebrospinal fluid exposure of cenicriviroc in HIV-positive individuals with cognitive impairment. <i>British Journal of Clinical Pharmacology</i> , <b>2019</b> , 85, 1039-1040	3.8	3
59	Depression, lifestyle factors and cognitive function in people living with HIV and comparable HIV-negative controls. <i>HIV Medicine</i> , <b>2019</b> , 20, 274-285	2.7	14

58	Brain Perfusion, Regional Volumes, and Cognitive Function in Human Immunodeficiency Virus-positive Patients Treated With Protease Inhibitor Monotherapy. <i>Clinical Infectious Diseases</i> , <b>2019</b> , 68, 1031-1040	11.6	2
57	Responses to Quadrivalent Influenza Vaccine Reveal Distinct Circulating CD4+CXCR5+ T Cell Subsets in Men Living with HIV. <i>Scientific Reports</i> , <b>2019</b> , 9, 15650	4.9	2
56	Risk factors and impact of patterns of co-occurring comorbidities in people living with HIV. <i>Aids</i> , <b>2019</b> , 33, 1871-1880	3.5	13
55	Tryptophan metabolism and its relationship with central nervous system toxicity in people living with HIV switching from efavirenz to dolutegravir. <i>Journal of NeuroVirology</i> , <b>2019</b> , 25, 85-90	3.9	8
54	Highlights of the 2017 European AIDS Clinical Society (EACS) Guidelines for the treatment of adult HIV-positive persons version 9.0. <i>HIV Medicine</i> , <b>2018</b> , 19, 309-315	2.7	62
53	No neurocognitive advantage for immediate antiretroviral treatment in adults with greater than 500 CD4+ T-cell counts. <i>Aids</i> , <b>2018</b> , 32, 985-997	3.5	11
52	Measurement of Retinal Vessels as a Biomarker of Cerebrovascular Aging in Older HIV-Positive Men Compared With Controls. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2018</b> , 77, 199-205 <sup>1</sup>	3.1	5
51	Cognitive Impairment in a Clinical Setting. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2018</b> , 77, e10-e13	3.1	5
50	Medicalising normality? Using a simulated dataset to assess the performance of different diagnostic criteria of HIV-associated cognitive impairment. <i>PLoS ONE</i> , <b>2018</b> , 13, e0194760	3.7	25
49	Chronic Kidney Disease Risk in African and Caribbean Populations With HIV. <i>Journal of Infectious Diseases</i> , <b>2018</b> , 218, 1767-1772	7	9
48	Clinical research cerebral MRI findings in HIV-positive subjects and appropriate controls. <i>Aids</i> , <b>2018</b> , 32, 2077-2081	3.5	4
47	Cardiovascular disease in women living with HIV: A narrative review. <i>Maturitas</i> , <b>2018</b> , 108, 58-70	5	13
46	Pain in people living with HIV and its association with healthcare resource use, well being and functional status. <i>Aids</i> , <b>2018</b> , 32, 2697-2706	3.5	30
45	Self-management Interventions for Pain and Physical Symptoms Among People Living With HIV: A Systematic Review of the Evidence. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2018</b> , 79, 206-225	3.1	11
44	Cohort profile: The Pharmacokinetic and clinical Observations in PeoPle over fifty (POPPY) study. <i>International Journal of Epidemiology</i> , <b>2018</b> , 47, 1391-1392e	7.8	27
43	Neuropharmacology. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , <b>2018</b> , 152, 55-64	3	1
42	Increased brain-predicted aging in treated HIV disease. <i>Neurology</i> , <b>2017</b> , 88, 1349-1357	6.5	133
41	An association between K65R and HIV-1 subtype C viruses in patients treated with multiple NRTIs. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2017</b> , 72, 2075-2082	5.1	6

40	Durability of viral suppression with first-line antiretroviral therapy in patients with HIV in the UK: an observational cohort study. <i>Lancet HIV, the</i> , <b>2017</b> , 4, e295-e302	7.8	38
39	Developing a Bayesian adaptive design for a phase I clinical trial: a case study for a novel HIV treatment. <i>Statistics in Medicine</i> , <b>2017</b> , 36, 754-771	2.3	8
38	Terminal differentiation of T cells is strongly associated with CMV infection and increased in HIV-positive individuals on ART and lifestyle matched controls. <i>PLoS ONE</i> , <b>2017</b> , 12, e0183357	3.7	27
37	High Cellular Monocyte Activation in People Living With Human Immunodeficiency Virus on Combination Antiretroviral Therapy and Lifestyle-Matched Controls Is Associated With Greater Inflammation in Cerebrospinal Fluid. <i>Open Forum Infectious Diseases</i> , <b>2017</b> , 4, ofx108	1	12
36	A first-in-human study of the novel HIV-fusion inhibitor C34-PEG-Chol. <i>Scientific Reports</i> , <b>2017</b> , 7, 9447	4.9	6
35	Changes in Cognitive Function Over 96 Weeks in Naive Patients Randomized to Darunavir-Ritonavir Plus Either Raltegravir or Tenofovir-Emtricitabine: A Substudy of the NEAT001/ANRS143 Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2017</b> , 74, 185-192	3.1	7
34	HIV-1 CNS in vitro infectivity models based on clinical CSF samples. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2016</b> , 71, 235-43	5.1	6
33	Tryptophan Metabolism and Its Relationship with Depression and Cognitive Impairment Among HIV-infected Individuals. <i>International Journal of Tryptophan Research</i> , <b>2016</b> , 9, 79-88	5.6	28
32	Defining cognitive impairment in people-living-with-HIV: the POPPY study. <i>BMC Infectious Diseases</i> , <b>2016</b> , 16, 617	4	45
31	CSF/plasma HIV-1 RNA discordance even at low levels is associated with up-regulation of host inflammatory mediators in CSF. <i>Cytokine</i> , <b>2016</b> , 83, 139-146	4	18
30	Evolution of changes in cognitive function after the initiation of antiretroviral therapy. <i>AIDS Research and Therapy</i> , <b>2016</b> , 13, 20	3	6
29	Host and disease factors are associated with cognitive function in European HIV-infected adults prior to initiation of antiretroviral therapy. <i>HIV Medicine</i> , <b>2016</b> , 17, 471-8	2.7	7
28	Neuroinflammation in treated HIV-positive individuals: A TSPO PET study. <i>Neurology</i> , <b>2016</b> , 86, 1425-1432	5	93
27	Simulation of the impact of rifampicin on once-daily darunavir/ritonavir pharmacokinetics and dose adjustment strategies: a population pharmacokinetic approach. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2016</b> , 71, 1041-5	5.1	4
26	Efficacy of protease inhibitor monotherapy vs. triple therapy: meta-analysis of data from 2303 patients in 13 randomized trials. <i>HIV Medicine</i> , <b>2016</b> , 17, 358-67	2.7	53
25	A Phase I study to assess the safety, tolerability and pharmacokinetic profile of boceprevir and sildenafil when dosed separately and together, in healthy male volunteers. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2015</b> , 70, 1812-5	5.1	1
24	Drug treatment for adults with HIV infection. <i>BMJ, The</i> , <b>2015</b> , 350, h1555	5.9	
23	Could antiretroviral neurotoxicity play a role in the pathogenesis of cognitive impairment in treated HIV disease?. <i>Aids</i> , <b>2015</b> , 29, 253-61	3.5	91

22	Differences in the direction of change of cerebral function parameters are evident over three years in HIV-infected individuals electively commencing initial cART. <i>PLoS ONE</i> , <b>2015</b> , 10, e0118608	3.7	11
21	Host, disease, and antiretroviral factors are associated with normalization of the CD4:CD8 ratio after initiating antiretroviral therapy. <i>Journal of Allergy and Clinical Immunology</i> , <b>2015</b> , 136, 1682-1685.e11-5	11.5	9
20	Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapine-containing combined antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2014</b> , 69, 1642-7	5.1	27
19	Adjudicated morbidity and mortality outcomes by age among individuals with HIV infection on suppressive antiretroviral therapy. <i>PLoS ONE</i> , <b>2014</b> , 9, e95061	3.7	56
18	Neurocognitive function in HIV-infected patients: comparison of two methods to define impairment. <i>PLoS ONE</i> , <b>2014</b> , 9, e103498	3.7	6
17	Cerebrospinal-fluid exposure of efavirenz and its major metabolites when dosed at 400 and 600 mg once daily; a randomized controlled trial. <i>Journal of the International AIDS Society</i> , <b>2014</b> , 17, 19541	5.4	3
16	Simulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIV-infected patients: a population PK approach. <i>Journal of the International AIDS Society</i> , <b>2014</b> , 17, 19586 <sup>4</sup>	5.4	3
15	Controversies in HIV-associated neurocognitive disorders. <i>Lancet Neurology, The</i> , <b>2014</b> , 13, 1139-1151	24.1	198
14	Can antiretroviral therapy prevent HIV-associated cognitive disorders?. <i>Current Opinion in HIV and AIDS</i> , <b>2014</b> , 9, 11-6	4.2	8
13	Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2013</b> , 68, 1354-9	5.1	26
12	Neurocognitive function in HIV infected patients on antiretroviral therapy. <i>PLoS ONE</i> , <b>2013</b> , 8, e61949	3.7	48
11	Dynamics of cognitive change in HIV-infected individuals commencing three different initial antiretroviral regimens: a randomized, controlled study. <i>HIV Medicine</i> , <b>2012</b> , 13, 245-51	2.7	30
10	Two patterns of cerebral metabolite abnormalities are detected on proton magnetic resonance spectroscopy in HIV-infected subjects commencing antiretroviral therapy. <i>Neuroradiology</i> , <b>2012</b> , 54, 1331-9	3.3	10
9	Overestimation or Underestimation of Neurocognitive Impairment in HIV-Infected Cohorts?. <i>HIV Clinical Trials</i> , <b>2012</b> , 13, 299-300		
8	Low rates of neurocognitive impairment are observed in neuro-asymptomatic HIV-infected subjects on effective antiretroviral therapy. <i>HIV Clinical Trials</i> , <b>2011</b> , 12, 333-8		63
7	Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatment-naive, HIV-1-infected individuals commencing cART? A randomized, controlled study. <i>Clinical Infectious Diseases</i> , <b>2010</b> , 50, 920-9	11.6	90
6	Does acute hepatitis C infection affect the central nervous system in HIV-1 infected individuals?. <i>Journal of Viral Hepatitis</i> , <b>2010</b> , 17, 419-26	3.4	21
5	Neuropsychiatric adverse events with ritonavir-boosted darunavir monotherapy in HIV-infected individuals: a randomised prospective study. <i>HIV Clinical Trials</i> , <b>2010</b> , 11, 163-9		25

4	48-week efficacy and safety of transitioning virologically stable HIV-1 patients from nevirapine IR 200 mg BID to nevirapine XR 400 mg QD (TRANxITION). <i>Journal of the International AIDS Society</i> , <b>2010</b> , 13, P45-P45	5.4	4
3	Changes in cerebral function parameters in HIV-1 infected subjects undergoing a treatment simplification to darunavir/ritonavir. <i>Journal of the International AIDS Society</i> , <b>2010</b> , 13, P52-P52	5.4	78
2	Clinical application of the inhibitory quotient: is there a role in HIV protease inhibitor therapy?. <i>Current Opinion in HIV and AIDS</i> , <b>2008</b> , 3, 608-11	4.2	6
1	The clinical pharmacology of antiretrovirals in development. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2006</b> , 2, 447-58	5.5	5